ETV6-related platelet disease is a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized clinical care are critical to improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological activation.
The platform can help align national and international authorities with teams to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to disease changes.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of ETV6-related platelet diseases. The platform serves a team of internationally authoritative experts in the field of blood tumours at home and abroad in China. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.